Saturday 17 October 2026
Export TLRY’s income statement to Excel — free account
Tilray Brands, Inc.
TLRY Healthcare Drug Manufacturers Specialty & Generic
Tilray Brands, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $915.5 million, up 11.5% from fiscal 2025. In the quarter to August 2026, revenue grew 22.7%, EPS was flat, free cash flow fell 36.6% and total debt rose 43.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.04
0.17
−5.30%
Follow TLRY
| Aug '26 | May '26 | Feb '26 | Nov '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.63 | 0.67 | 1.00 | 1.03 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(36.84) | (16.45) | (39.03) | (100.82) | |
P/B ratio |
0.38 | 0.39 | 0.56 | 0.56 | |
Price to Tangible BV |
0.75 | 0.77 | 1.14 | 1.11 | |
EV/Sales |
0.77 | 0.83 | 1.04 | 1.04 | |
EV/EBITDA |
0.00 | 60.51 | 0.00 | 0.00 | |
EV/Operating CF |
(8.77) | (10.93) | (20.00) | (30.68) | |
EV/FCF |
(4.24) | (4.81) | (6.95) | (8.58) | |
Quick Ratio |
0.96 | 1.18 | 1.49 | 1.54 | |
Current Ratio |
1.88 | 2.21 | 2.79 | 2.81 | |
Net Debt/EBITDA |
(32.90) | 13.11 | (2.66) | (2.79) | |
Debt/Assets |
15.09% | 16.16% | 14.51% | 14.47% | |
Debt/Equity |
0.22 | 0.24 | 0.20 | 0.20 | |
Asset Turnover |
0.44 | 0.42 | 0.31 | 0.27 | |
Operating CF/Net income |
0.38 | 0.75 | 0.83 | 0.19 | |
Capex/Depreciation |
(0.54) | (1.15) | (0.18) | (0.53) | |
Interest Coverage |
(3.71) | (2.48) | (5.31) | (4.15) | |
Research and Development Expense of Revenue |
0.03% | 0.06% | 0.03% | 0.04% | |
Selling, General and Administrative Expense of Revenue |
33.81% | 31.47% | 33.64% | 33.53% | |
Intangible Assets out of Total Assets |
0.34 | 0.34 | 0.37 | 0.37 | |
Share Based Compensation of Revenue |
2.56% | 5.28% | 6.64% | 5.65% | |
Graham Net Nets |
0.14 | 0.10 | 0.20 | 0.21 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(30.20%) | (19.67%) | (179.61%) | (283.46%) | |
Free Cash Flow Yield |
(28.63%) | (25.61%) | (14.99%) | (11.81%) | |
Revenue per Share |
1.93 | 2.52 | 1.83 | 1.97 | |
Operating CF per Share |
(0.12) | (0.33) | (0.19) | (0.08) | |
Capex per Share |
(0.08) | (0.28) | (0.02) | (0.09) | |
Free Cash Flow per Share |
(0.21) | (0.61) | (0.21) | (0.16) | |
Cash per Share |
1.66 | 2.10 | 2.35 | 2.64 | |
Shareholders Equity per Share |
12.05 | 14.26 | 13.54 | 14.02 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
12.05 | 14.26 | 13.54 | 14.02 | |
Free Cash Flow |
(27.45) | (68.60) | (24.19) | (18.10) | |
Working Capital |
376.90 | 433.75 | 461.22 | 470.00 | |
Capital Expenditures |
(10.91) | (31.28) | (2.25) | (9.56) | |
Net Current Asset Value |
86.31 | 58.99 | 169.65 | 177.23 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.11 | 0.01 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
148.85 | 155.33 | 110.87 | 110.91 | |
Average Payables |
283.16 | 276.71 | 220.28 | 224.05 | |
Average Inventory |
305.88 | 286.04 | 277.85 | 274.60 | |
Average Assets |
2,205.30 | 2,201.17 | 2,738.93 | 3,145.18 | |
Average Common Equity |
1,563.67 | 1,542.22 | 2,113.86 | 2,500.06 |
Columns are period end dates · fundamentals updated 13 Oct 2026